Spike S1 RBD (B.1.1.529 BA.1, Omicron Variant) (SARS-CoV-2): ACE2 Inhibitor Screening Colorimetric Assay Kit
The Spike S1 RBD (B.1.1.529 BA.1, Omicron Variant) (SARS-CoV-2): ACE2 Inhibitor Screening Colorimetric Assay Kit is designed for screening and profiling inhibitors or neutralizing antibodies of the interaction between the Omicron variant SARS-CoV-2 Spike RBD and human ACE2.
The assay requires only a few steps. First, SARS-CoV-2 Spike RBD (B.1.1.529 BA.1, Omicron Variant) is coated on a 96-well plate overnight. After washing and blocking, the protein is pre-incubated with an inhibitor or neutralizing antibody. Upon subsequent incubation with Biotin-ACE2, the plate is treated with Streptavidin-HRP followed by addition of a colorimetric HRP substrate to produce color, which can be quenched and measured using a UV/Vis microplate reader.
Assay Principle
PBS (Phosphate buffered saline)
1N HCl (aqueous)
Rotating or rocker platform
UV/Vis spectrophotometer microplate reader capable of reading absorbance at 450 nm*
| Catalog # | Name | Amount | Storage |
| 101356 | Spike S1 RBD (B.1.1.529 BA.1, Omicron Variant), Avi-His-Tag (SARS-CoV-2)* | 5 µg | -80°C |
| 100665 | ACE2, His-Avi-Tag, Biotin labeled * | 2 x 5 µg | -80°C |
| 79311 | 3x Immuno Buffer 1 | 50 ml | -20°C |
| 79728 | Blocking Buffer 2 | 50 ml | +4°C |
| 79742 | Streptavidin-HRP | 10 µl | +4°C |
| 79651 | Colorimetric HRP substrate | 10 ml | +4°C |
| 79964 | Transparent 96-well microplate | 1 | Room Temp |
*The initial concentration of both ACE2 and Spike RBD is lot-specific and will be indicated on the tube containing the protein.
The COVID-19 pandemic is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). The Spike glycoprotein is expressed on the surface of the virus as a trimer. Each Spike protein consists of two subunits, S1 and S2, and the S1 subunit contains the receptor binding domain (RBD) which recognizes and attaches to the ACE2 receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. SARS-CoV-2 Variant B.1.1.529 BA.1, also known as Omicron variant, was originally discovered in South Africa and has recently become a global variant of concern.
Drugs targeting the interaction between SARS-CoV-2 Spike protein and human ACE2 may offer some protection against viral infection. The SARS-CoV-2 Spike RBD (B.1.1.529 BA.1, Omicron Variant) protein in this kit consists of the RBD region of the S1 protein, which includes the ACE2 binding site.
Powered by Bioz
San Diego, CA 92121
858-202-1401
Products are for Research Use Only
COMPANY
Copyright © 2024
BPS Bioscience, Inc.
All rights reserved.
Diagrams on this website are created with BioRender.com.